Pirbuterol
Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma, available (as pirbuterol acetate) as a breath-activated metered-dose inhaler.
Clinical data | |
---|---|
Trade names | Maxair |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a601096 |
Pregnancy category |
|
Routes of administration | Inhalational (MDI) |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H20N2O3 |
Molar mass | 240.303 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
SMILES
| |
InChI
| |
(what is this?) (verify) |
It was patented in 1971 and came into medical use in 1983.[1]
Medical use
Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid.[2][3]
Mode of action
Pharmacokinetics
After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase. The plasma half-life measured after oral administration is about two hours.[2]
Adverse effects
References
- Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 543. ISBN 9783527607495.
- "Maxair Autohaler (pirbuterol acetate inhalation aerosol) For Oral Inhalation Only. U.S. Full Prescribing Information". 3M Pharmaceuticals. Northridge, CA 91324. Archived from the original on 20 September 2018. Retrieved 7 March 2016.
- Bianchi M, Clavenna A, Bonati M (September 2010). "Inter-country variations in anti-asthmatic drug prescriptions for children. Systematic review of studies published during the 2000-2009 period" (PDF). European Journal of Clinical Pharmacology. 66 (9): 929–36. doi:10.1007/s00228-010-0845-y. PMID 20533030. S2CID 21834280.